Mar. 16 at 12:20 PM
JPMorgan⬆️
$SRRK's PT to
$50 from
$47AND reiterated at an Overweight rating.
$RHHBY $BIIB LLY NVO
JPMorgan said in its note—We continue to recommend SRRK into the balance of 2026 and believe apiteg romab should be approved with a broad label (2yo+) and see a strong launch in SMA given the clinical data and high unmet need.
We see the drug growing to be a >
$2B product in worldwide sales over time.
Notably, we recently attended the Muscular Dystrophy Association (MDA) conference (Mar. 8-11, 2026; Orlando, FL) in-person and had the opportunity to attend several sessions focused on spinal muscular atrophy (SMA) where KOLs emphasized the urgency to diagnose and treat early (i.e., time is muscle); we heard in our conversations with KOLs that the focus for apitegromab's use, if approved, will be on patients who are showing functional decline despite treatment with currently available SMN-targeted therapies.
